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Background: Late cardiotoxicity after anthracycline therapy has been well documented in the pediatric cancer population. However, the spectrum 
and prevalence of cardiac abnormalities in asymptomatic adult survivors of childhood cancer is less well defined.
Methods:  114 consecutive adult survivors (age >18) of childhood and young adult cancer with past anthracycline exposure seen at the Adult 
Survivorship Program from 7/09-8/10 were included. Clinical information and echocardiographic data were analyzed. The patients were divided into 
3 groups based on cumulative anthracycline dose.
Results:  The age of the cohort ranged from 19 to 57 years and nearly half were men. Follow-up time since treatment varied from 3 to 45 years. 
Fractional shortening (FS), LV cavity size and LV mass were lower in patients treated with anthracycline than in an age-matched control group. Twenty 
percent of the cohort demonstrated reduced FS of <30% which was directly related to the cumulative anthracycline dose but showed no change in 
relation to time since treatment. LV mass and wall thickness were similar between the 3 groups but showed no correlation to age or body mass index. 
N = 114
Age, mean (SD) 31 ± 8
Age at diagnosis 14 ± 8
Male sex, N (%) 64 (56%)
Hypertension, N (%) 14 (12%)
Diabetes, N (%) 3 (3%)
Body mass index 25.0 ±5.6
Time since treatment (years) 16.9 ± 9.0
Chest irradiation, N (%) 51 (45%)
Cumulative anthracyclines (mg/m2) 236 ±153
Cumulative anthracyclines (mg/m2)
Overall <300 300-400 >400
N 114 64 34 16 p-value* Ref #
FS % 32 ± 4 33 ± 4 31 ± 3 32 ± 4 0.21 36 ±5
FS < 30%, % (N) 20% (23) 14% (9) 27% (9) 31% (5) 0.39
Ejection fraction % 59 ± 5 60 ± 6 59 ± 4 59 ± 6 0.39 63 ± 6 
LV mass/height2.7 30 ± 7 30 ± 8 29 ± 6 32 ±5 0.99 33 ± 7
Wall thickness 0.74 ± 0.1 0.74 ± 0.1 0.74 ± 0.1 0.77 ± 0.1 0.41
End diastolic dimension (cm) 4.7 ± 0.5 4.7 ± 0.5 4.6 ± 0.4 4.9 ± 0.4 0.47 5.1 ± 0.4
* adjusted for age, hypertension, and history of irradiation; # CARDIA study
Conclusions: There is a high prevalence of cardiac abnormalities in asymptomatic adult survivors of childhood cancer. LV systolic dysfunction was 
common and the expected response of LV mass to physiologic changes was not observed . Longitudinal studies are needed to define the clinical 
significance of these findings.
